The guidance cut signals worsening payer mix from exchange losses, a structural headwind that may persist through 2026. The full Q2 earnings call on July 24 will provide more detail on volume trends and cost mitigation. Monitor for further deterioration in exchange enrollment and any offset from Medicaid programs.
Price Chart
Executive Summary
HCA Healthcare issued preliminary Q2 2026 results and revised 2026 guidance downward. Q2 revenue grew 8.7% YoY to ~$20.23B and EPS rose to $7.62, but a $400M unfavorable payer mix shift from health insurance exchange losses drove a guidance cut: 2026 EPS guidance lowered to $28.70-$30.50 (from $29.10-$31.50) and net income guidance reduced by ~$195M-$335M at the midpoint. The Medicaid Supplemental Payment Programs provided a $400M offset in Q2, but the net outlook is negative.
Key Financial Metrics
Key Facts
- Preliminary Q2 2026 revenue ~$20.23B (+8.7% YoY), net income ~$1.699B ($7.62 EPS) vs $1.653B ($6.83) in Q2 2025
- Same facility admissions +2.5%, equivalent admissions +2.7%, ER visits +3.6%
- Payer mix shift from health insurance exchanges had ~$400M unfavorable impact on Q2 income before taxes
- Medicaid Supplemental Payment Programs provided ~$400M incremental net benefit in Q2, primarily from Florida
- 2026 guidance revised: EPS $28.70-$30.50 (from $29.10-$31.50), net income $6.3B-$6.7B (from $6.495B-$7.035B), Adjusted EBITDA $15.4B-$16.1B (from $15.55B-$16.45B)
- Health Insurance Exchanges assumption worsened to ($1.0B-$1.2B) from ($600M-$900M); Medicaid Supplemental improved to $300M-$500M from ($50M-$250M)
- Capital expenditure guidance unchanged at $5.0B-$5.5B
Financial Impact
2026 EPS guidance lowered by $0.40-$1.00 per share; net income guidance reduced by ~3-5% at midpoint
Risk Factors
- Further adverse payer mix shifts if exchange enrollment declines continue
- Potential for additional guidance cuts if surgical volume remains weak
- Medicaid supplemental payments are subject to regulatory approval and may not recur at same levels
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-302539 |
| Document: hca-20260714.htm | 0001193125-26-302539 |
| Document: 0001193125-26-302539-index-headers.html | 0001193125-26-302539 |
| Document: 0001193125-26-302539-index.html | 0001193125-26-302539 |
| Document: 0001193125-26-302539.txt | 0001193125-26-302539 |
| 8-K Data (Synthetic) | 0001193125-26-302539 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 24, 2026 10w ago | 8-K | $382.19 $429.19 | ▲ +12.30% | ▲ +8.67% | $426.69 (+11.64%) |
Jul 14, 2026 11w ago | 8-K | $363.60 $411.44 | ▼ −13.16% | ▼ −10.67% | $426.69 (−17.35%) |
Jun 18, 2026 15w ago | 8-K | $375.17 $385.74 | ▲ +2.82% | ▲ +2.28% | $426.69 (+13.73%) |
Apr 27, 2026 22w ago | 8-K | $431.48 $392.42 | ▼ −9.05% | ▼ −14.52% | $426.69 (−1.11%) |
Apr 27, 2026 22w ago | Court Ruling | $445.70 $392.48 | ▼ −11.94% | ▼ −16.87% | $426.69 (−4.26%) |
Apr 24, 2026 23w ago | 8-K | $432.55 $392.56 | ▼ −9.25% | ▼ −13.27% | $426.69 (−1.36%) |
Mar 13, 2026 29w ago | DEFA14A | $525.04 $496.74 | ▼ −5.39% | ▼ −9.17% | $426.69 (−18.73%) |
Feb 25, 2026 31w ago | 8-K | $525.78 $479.78 | ▼ −8.75% | ▼ −2.35% | $426.69 (−18.85%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access